Soluble P-selectin levels in patients with obstructive sleep apnea: a systematic review and meta-analysis
Authors:
- 5 May 2021
- journal article
- review article
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 278 (12) , 4633-4644
Abstract
Purpose Obstructive sleep apnea (OSA) patients are at increased risk for cardiovascular disease, stroke, atherosclerosis, hypertension, and venous thromboembolism. Elevated soluble P-selectin (sP-selectin) levels are also associated with increased risk of above diseases. But whether sP-selectin levels in OSA patients are higher than their counterparts remain unclear, since previous studies yielded inconsistent results. Therefore, a meta-analysis is warranted. Methods PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies. Studies were included if they reported sP-selectin levels of both OSA patients and non-OSA controls. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated to determine the effect sizes. Results Nine eligible studies were finally evaluated. When all the studies were pooled, sP-selectin levels in OSA patients were significantly higher than that in controls (SMD = 0.54, 95% CI 0.29–0.78, I2 = 66%, p < 0.0001). In the subgroup analysis based on BMI matched groups, sP-selectin levels were significantly higher in OSA patients than that in controls (SMD = 0.52, 95% CI 0.27–0.76, I2 = 23%, p < 0.0001). In the subgroup analysis stratified by blood source, either serum sP-selectin levels or plasma sP-selectin levels in OSA patients were higher than that in controls. Moderate-to-severe OSA patients had significant higher sP-selectin levels (SMD = 0.80, 95% CI 0.45–1.15, I2 = 67%, p < 0.00001), while mild OSA patients showed no significant difference with controls. Conclusion The pooled results reveal that OSA patients have higher sP-selectin levels than non-OSA controls. This conclusion remains unaltered in all subgroups other than the subgroup of mild OSA patients. Additional studies are warranted to better identify the role of sP-selectin as a potential biomarker in OSA patients.Keywords
This publication has 54 references indexed in Scilit:
- Obstructive Sleep ApneaChest, 2011
- New in vitro effects of clopidogrel on platelets in hyperlipidemic and healthy subjectsTurkish Journal of Hematology, 2010
- OSA: the new cardiovascular diseaseHeart Failure Reviews, 2008
- Effects of depressive and anxious symptoms on norepinephrine and platelet P-selectin responses to acute psychological stress among elderly caregiversBrain, Behavior, and Immunity, 2008
- sP-selectin plasma levels in obesity: Association with insulin resistance and related metabolic and prothrombotic factorsNutrition, Metabolism and Cardiovascular Diseases, 2008
- Obstructive Sleep Apnea as a Risk Factor for Stroke and DeathNew England Journal of Medicine, 2005
- Effect of P-Selectin on Phosphatidylserine Exposure and Surface-Dependent Thrombin Generation on MonocytesArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Adiponectin in Patients with Obstructive Sleep Apnea Syndrome: Course and Physiological RelevanceRespiration, 2004
- Re‐expression of functional P‐selectin molecules on the endothelial cell surface by repeated stimulation with thrombinBritish Journal of Haematology, 1997
- Influence Of Hypoxia And Hypoxia-Reoxygenation On Endothelial P-Selectin ExpressionPathophysiology of Haemostasis and Thrombosis, 1996